RECBIO-B(02179) received approval from the China Securities Regulatory Commission for a targeted issuance of domestic shares.
Ruikang Biology-B (02179) announced that on July 23, 2025, the company received a notice from the China Securities Regulatory Commission ""
RECBIO-B(02179) announced that on July 23, 2025, the company received the approval from the China Securities Regulatory Commission for the issuance of shares to specific investors by Jiangsu Ruikang Biotechnology Co., Ltd. (CSRC License [2025] No. 1506). The CSRC has approved the issuance.
Related Articles
US Stock Market Move | Futu Holdings Ltd. Sponsored ADR Class A (FUTU.US) rose more than 5% after reaching a strategic cooperation agreement on Web3.0 with Huaxia Fund Hong Kong.
US Stock Market Move | Nuclear power stocks collectively surged, with Oklo Inc (OKLO.US) rising more than 13%.
China Silver Technology (00515) appoints Chang Qing as the new auditor.
US Stock Market Move | Futu Holdings Ltd. Sponsored ADR Class A (FUTU.US) rose more than 5% after reaching a strategic cooperation agreement on Web3.0 with Huaxia Fund Hong Kong.
US Stock Market Move | Nuclear power stocks collectively surged, with Oklo Inc (OKLO.US) rising more than 13%.
China Silver Technology (00515) appoints Chang Qing as the new auditor.
RECOMMEND
Backed by BYD, Why Has the Leading EV Charger Firm Seen Revenue Declines and Surging Losses?
23/07/2025
Just Days Away from Losing Tens of Millions of Dollars! Copper-Laden Ships Race Toward U.S. Ports
23/07/2025
Japan "Surrenders"? Trump Claims "U.S. and Japan Reach Deal: Japan Accepts 15% Tariff Rate, Opens Auto and Rice Markets, Pledges $550 Billion in U.S. Investments"
23/07/2025
